Role of bile acid sequestrants in the treatment of type 2 diabetes

Diabetes Care

Volumn 34, Issue SUPPL. 2, 2011, Pages

  Handelsman, Yehuda ^a  

^a Metabolic Institute of America   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; COLESEVELAM; COLESTILAN; COLESTYRAMINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; PROTEIN TGR5; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ALLYLAMINE; ANTILIPEMIC AGENT; BILE ACID; COLESTIPOL; DRUG DERIVATIVE; EPICHLOROHYDRIN; IMIDAZOLE DERIVATIVE; RESIN;

ADD ON THERAPY; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; EDEMA; FLATULENCE; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HIGH RISK PATIENT; HORMONE RELEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ALLYLAMINE; BILE ACIDS AND SALTS; CHOLESTYRAMINE RESIN; COLESTIPOL; DIABETES MELLITUS, TYPE 2; EPICHLOROHYDRIN; HYPOLIPIDEMIC AGENTS; IMIDAZOLES; RESINS, SYNTHETIC;

EID: 79959785811     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-s237     Document Type: Review

References (50)

1. Campbell RK. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc 2009;49(Suppl. 1):S3-S9
2. Glucotrol XL (glipizide extended release tablets) prescribing information [Internet], 2006. Available from http://www.pfizer.com/files/products/uspi- glucotrol-xl.pdf. Accessed 1 April 2010
3. Micronase (glyburide tablets) prescribing information [Internet], 2009. Available from http://media.pfizer.com/files/products/uspi-micronase.pdf. Accessed 1 April 2010
4. Amaryl (glimepiride tablets) prescribing information [Internet], 2009. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 020496s021lbl.pdf. Accessed1 April 2010
5. Avandia (rosiglitazone maleate tablets) prescribing information [Internet], 2008. Available from http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM143472.pdf. Accessed 1 April 2010
6. Actos (pioglitazone hydrochloride tablets) prescribing information [Internet], 2009. Available from http://www.actos.com/actospro/prescribinginfo. aspx. Accessed1 April 2010
7. Glucophage (metformin hydrochloride tablets) prescribing information [Internet], 2009. Available from http://packageinserts.bms.com/pi/pi-glucophage. pdf. Accessed1 April 2010
8. Januvia (sitagliptin tablets) prescribing information [Internet], 2010. Available from http://www.merck.com/product/usa/pi-circulars/j/januvia/januvia- pi.pdf. Accessed 1 April 2010
9. Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007;99:47C-55C
10. Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364
11. Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374
12. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: a short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-422
13. Kondo K, Kadowaki T. Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study. Diabetes Obes Metab 2010;12:246-251
14. Suzuki T, Oba K, Futami S, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006;73:277-284 (Pubitemid 44663094)
15. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83 (Pubitemid 46414026)
16. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin 2007;23:1673-1684 (Pubitemid 47122177)
17. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetesmellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168:1975-1983
18. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-1484
19. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-1540
20. Goldfine AB. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr Opin Cardiol 2008;23:502-511
21. Staels B. A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus. Postgrad Med 2009;121(Suppl. 1):25-30
22. Suzuki T,Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007;74:338-343 (Pubitemid 47523077)
23. Beysen C, Deines KC, Tsang EL, et al. Colesevelam HCl improves glucose metabolism and increases plasma glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide concentrations in subjects with type 2 diabetes. Presented at the Annual Meeting of the European Association for the Study of Diabetes. Vienna, Austria, September 29-October 2, 2009
24. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2006;185:327-330
25. Goldfine AB, Fonseca VA, Jones MR, Wang AC, Ford DM, Truitt KE. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res 2010;42:23-30
26. Goldberg RB, Truitt K. Colesevelam HCl improves glycemic control in type 2 diabetes mellitus subjects managed with insulin therapy. Presented at the American Heart Association Scientific Sessions. Chicago, IL, November 12-15, 2006
27. Goldfine AB, Fonseca VA, Abby SL, Jones MR. The use of colesevelam HCl with concomitant statin therapy in type 2 diabetes mellitus improves glycemic control and the lipid profile. Presented at the National Lipid Association Annual Scientific Sessions. Seattle, WA, 2008
28. American Diabetes Association. Standards of medical care in diabetes: 2010. Diabetes Care 2010;33(Suppl. 1):S11-S61
29. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement fromthe American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 2008;14:933-946
30. Santaguida PL, Balion C, Hunt D, et al. Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose. Rockville,MD, Agency for Healthcare Research and Quality Evidence Report/Technology assessment no. 128 (prepared by the McMaster University Evidence-Based Practice Center under contract no. 290-02-0020)
31. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010;55:1310-1317
32. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-811
33. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes: implications for clinical practice. Prim Care 1999;26:771-789 (Pubitemid 29523599)
34. Handelsman Y. The role of colesevelam HCl in type 2 diabetes mellitus therapy. Postgrad Med 2009;121(Suppl. 1):19-24
35. Handelsman Y, Abby SL, Jin X, Donovan JM, Jones MR. Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med 2009;121:62-69
36. Jones MR, Mudaliar S, Hernandez-Triana E, et al. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Curr Med Res Opin 2009;25:2239-2249
37. Handelsman Y, Goldberg RB, Garvey WT, et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract 2010;16:617-628
38. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl. 1):1-68
39. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559
40. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803 (Pubitemid 34970933)
41. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
42. Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract 2010;16:53-63
43. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 1998;15:651-656
44. Rosenstock J, Fonseca VA, Garvey WT, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract 2010;16:629-640
45. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-822
46. Joslin Diabetes Center and Joslin Clinic. Clinical guideline for pharmacological management of type 2 diabetes [Internet], 2009. Available from http://www.joslin.org/bin-from-cms/Pharma-guideline-11.-10.pdf. Accessed 14 March 2010
47. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
48. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559 (Pubitemid 351831356)
49. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
50. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119:351-357